Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,427
  • Shares Outstanding, K 143,879
  • Annual Sales, $ 148,760 K
  • Annual Income, $ -264,520 K
  • 60-Month Beta 1.58
  • Price/Sales 0.80
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.10
  • Most Recent Earnings -0.44 on 05/04/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 193.90% ( +10.64%)
  • Historical Volatility 151.05%
  • IV Percentile 98%
  • IV Rank 75.05%
  • IV High 240.88% on 05/11/22
  • IV Low 52.56% on 08/10/21
  • Put/Call Vol Ratio 0.66
  • Today's Volume 282
  • Volume Avg (30-Day) 3,689
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 102,024
  • Open Int (30-Day) 97,777

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.43
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +32.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7020 +5.41%
on 05/12/22
2.4800 -70.16%
on 04/25/22
-1.5000 (-66.96%)
since 04/18/22
3-Month
0.7020 +5.41%
on 05/12/22
3.1400 -76.43%
on 04/06/22
-0.9700 (-56.73%)
since 02/18/22
52-Week
0.7020 +5.41%
on 05/12/22
7.2400 -89.78%
on 06/09/21
-4.7500 (-86.52%)
since 05/18/21

Most Recent Stories

More News
2 Biotech Stocks That Could Go Parabolic

These gems are hiding in a sector that has been pummeled so far this year.

AXSM : 31.54 (-6.08%)
CLVS : 0.7320 (-6.15%)
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

ALKS : 29.00 (-2.32%)
VRTX : 255.28 (-2.51%)
CLVS : 0.7320 (-6.15%)
VTRS : 11.40 (-0.61%)
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.

VRTX : 255.28 (-2.51%)
ALC : 71.43 (-0.97%)
JAZZ : 149.90 (-1.58%)
CLVS : 0.7320 (-6.15%)
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results

Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.

ENDP : 0.6389 (-44.92%)
ALKS : 29.00 (-2.32%)
VRTX : 255.28 (-2.51%)
CLVS : 0.7320 (-6.15%)
STERIS (STE) to Report Q4 Earnings: What's in the Cards?

Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.

VRTX : 255.28 (-2.51%)
JAZZ : 149.90 (-1.58%)
STE : 219.50 (-0.96%)
CLVS : 0.7320 (-6.15%)
Why Clovis Oncology Stock Was Plummeting This Week

Investors bailed from the company after a quarterly results and operational update.

CLVS : 0.7320 (-6.15%)
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

VRTX : 255.28 (-2.51%)
CLVS : 0.7320 (-6.15%)
GBT : 27.36 (-4.40%)
VYGR : 6.29 (-4.12%)
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May...

CLVS : 0.7320 (-6.15%)
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

BMY : 77.47 (-0.96%)
VRTX : 255.28 (-2.51%)
CLVS : 0.7320 (-6.15%)
DCPH : 10.93 (-4.37%)
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 0.7320 (-6.15%)
SPRO : 1.5100 (-8.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with...

See More

Key Turning Points

3rd Resistance Point 0.9309
2nd Resistance Point 0.9005
1st Resistance Point 0.8409
Last Price 0.7320
1st Support Level 0.7509
2nd Support Level 0.7205
3rd Support Level 0.6609

See More

52-Week High 7.2400
Fibonacci 61.8% 4.7425
Fibonacci 50% 3.9710
Fibonacci 38.2% 3.1995
Last Price 0.7320
52-Week Low 0.7020

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar